Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival.

Vuppalanchi R, Carbone M

Open source

DOI
10.1097/hep.0000000000001903
Published
2026 Nov 5
Container
Hepatology (Baltimore, Md.)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000001903,
  title = {Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival.},
  author = {Vuppalanchi R and Carbone M},
  year = {2026},
  journal = {Hepatology (Baltimore, Md.)},
  doi = {10.1097/hep.0000000000001903},
  url = {https://doi.org/10.1097/hep.0000000000001903}
}

RIS

TY  - JOUR
TI  - Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival.
AU  - Vuppalanchi R
AU  - Carbone M
PY  - 2026
JO  - Hepatology (Baltimore, Md.)
DO  - 10.1097/hep.0000000000001903
UR  - https://doi.org/10.1097/hep.0000000000001903
ER  - 

APA

R, V., & M, C. (2026). Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival.. Hepatology (Baltimore, Md.). https://doi.org/10.1097/hep.0000000000001903

Source records